Literature DB >> 26068781

A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.

Susan E Maslanka1, Carolina Lúquez1, Janet K Dykes1, William H Tepp2, Christina L Pier2, Sabine Pellett2, Brian H Raphael1, Suzanne R Kalb1, John R Barr1, Agam Rao1, Eric A Johnson2.   

Abstract

Botulism is a potentially fatal paralytic disease caused by the action of botulinum neurotoxin (BoNT) on nerve cells. There are 7 known serotypes (A-G) of BoNT and up to 40 genetic variants. Clostridium botulinum strain IBCA10-7060 was recently reported to produce BoNT serotype B (BoNT/B) and a novel BoNT, designated as BoNT/H. The BoNT gene (bont) sequence of BoNT/H was compared to known bont sequences. Genetic analysis suggested that BoNT/H has a hybrid-like structure containing regions of similarity to the structures of BoNT/A1 and BoNT/F5. This novel BoNT was serologically characterized by the mouse neutralization assay and a neuronal cell-based assay. The toxic effects of this hybrid-like BoNT were completely eliminated by existing serotype A antitoxins, including those contained in multivalent therapeutic antitoxin products that are the mainstay of human botulism treatment. Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  Clostridium botulinum; botulinum toxin; botulism; neuronal cell-based assay; neutralization; serotype

Mesh:

Substances:

Year:  2015        PMID: 26068781      PMCID: PMC4704661          DOI: 10.1093/infdis/jiv327

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  37 in total

1.  Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-03-19       Impact factor: 17.586

2.  Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.

Authors:  T J Smith; J Lou; I N Geren; C M Forsyth; R Tsai; S L Laporte; W H Tepp; M Bradshaw; E A Johnson; L A Smith; J D Marks
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Notes on Bacillus botulinus.

Authors:  G S Burke
Journal:  J Bacteriol       Date:  1919-09       Impact factor: 3.490

Review 4.  Historical and current perspectives on Clostridium botulinum diversity.

Authors:  Theresa J Smith; Karen K Hill; Brian H Raphael
Journal:  Res Microbiol       Date:  2014-10-12       Impact factor: 3.992

5.  Human botulism immune globulin for the treatment of infant botulism.

Authors:  Stephen S Arnon; Robert Schechter; Susan E Maslanka; Nicholas P Jewell; Charles L Hatheway
Journal:  N Engl J Med       Date:  2006-02-02       Impact factor: 91.245

6.  Enhancing the protective immune response against botulism.

Authors:  Amanda Przedpelski; William H Tepp; Abby R Kroken; Zhuji Fu; Jung-Ja P Kim; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2013-05-13       Impact factor: 3.441

7.  Molecular characterization of a novel botulinum neurotoxin type H gene.

Authors:  Nir Dover; Jason R Barash; Karen K Hill; Gary Xie; Stephen S Arnon
Journal:  J Infect Dis       Date:  2013-10-07       Impact factor: 5.226

8.  A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.

Authors:  Jason R Barash; Stephen S Arnon
Journal:  J Infect Dis       Date:  2013-10-07       Impact factor: 5.226

9.  Atypical toxin variant of Clostridium botulinum type B associated with infant botulism.

Authors:  C L Hatheway; L M McCroskey; G L Lombard; V R Dowell
Journal:  J Clin Microbiol       Date:  1981-12       Impact factor: 5.948

10.  Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin.

Authors:  Dorothea Sesardic; Tong Leung; Rose Gaines Das
Journal:  Biologicals       Date:  2003-12       Impact factor: 1.856

View more
  66 in total

Review 1.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

Review 2.  Bacterial Signaling to the Nervous System through Toxins and Metabolites.

Authors:  Nicole J Yang; Isaac M Chiu
Journal:  J Mol Biol       Date:  2017-01-06       Impact factor: 5.469

3.  Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").

Authors:  Sabine Pellett; William H Tepp; Guangyun Lin; Eric A Johnson
Journal:  Toxicon       Date:  2017-12-19       Impact factor: 3.033

4.  Selection of RNA Aptamers Against Botulinum Neurotoxin Type A Light Chain Through a Non-Radioactive Approach.

Authors:  Tzuu-Wang Chang; Pavithra Janardhanan; Charlene M Mello; Bal Ram Singh; Shuowei Cai
Journal:  Appl Biochem Biotechnol       Date:  2016-04-16       Impact factor: 2.926

5.  Novel Native and Engineered Botulinum Neurotoxins.

Authors:  Lance Steward; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Handb Exp Pharmacol       Date:  2021

6.  Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.

Authors:  Kwok-Ho Lam; Stefan Sikorra; Jasmin Weisemann; Hannah Maatsch; Kay Perry; Andreas Rummel; Thomas Binz; Rongsheng Jin
Journal:  Pathog Dis       Date:  2018-06-01       Impact factor: 3.166

7.  Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review.

Authors:  Edith Schussler; Jeremy Sobel; Joy Hsu; Patricia Yu; Dana Meaney-Delman; Leslie C Grammer; Anna Nowak-Wegrzyn
Journal:  Clin Infect Dis       Date:  2017-12-27       Impact factor: 9.079

8.  Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin.

Authors:  Patricia A Yu; Neal H Lin; Barbara E Mahon; Jeremy Sobel; Yon Yu; Rajal K Mody; Weidong Gu; Jennifer Clements; Hye-Joo Kim; Agam K Rao
Journal:  Clin Infect Dis       Date:  2017-12-27       Impact factor: 9.079

9.  Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium.

Authors:  Sicai Zhang; Francois Lebreton; Michael J Mansfield; Shin-Ichiro Miyashita; Jie Zhang; Julia A Schwartzman; Liang Tao; Geoffrey Masuyer; Markel Martínez-Carranza; Pål Stenmark; Michael S Gilmore; Andrew C Doxey; Min Dong
Journal:  Cell Host Microbe       Date:  2018-01-27       Impact factor: 21.023

10.  Purification and Characterization of Recombinant Botulinum Neurotoxin Serotype FA, Also Known as Serotype H.

Authors:  Gavin Hackett; Kevin Moore; David Burgin; Fraser Hornby; Bryony Gray; Mark Elliott; Imran Mir; Matthew Beard
Journal:  Toxins (Basel)       Date:  2018-05-11       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.